Skip to main content
OpenTrials
Completed

NCT Number: NCT03808623

Non-interventional Study With NOVOCART® Basic in Patients Treated for Cartilage Defects in the Knee With MAC

Retrospective, multicenter, single arm, non-interventional study to assess the safety and Performance of NOVOCART Basic and the clinical outcome of MAC with NOVOCART Basic in patients treated for cartilage defects in the knee.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Theresienkrankenhaus und St. Hedwig-Klinik GmbH, Mannheim, Baden-Wurttemberg, Germany

Loading trial locations.

About this study

This study is a multi-center, single arm, non-interventional study to assess the safety and performance of NOVOCART® Basic and the clinical outcome of MAC with NOVOCART® Basic in patients treated for cartilage defects in the knee. In this study data will be collected retrospectively from patient files of adult and pediatric patients who had received an MAC with NOVOCART® Basic for cartilage defects in the knee according to medical practice. In addition, at the time when a patient consents to participate in the study, he/she will have to fill-out questionnaires on current symptoms and knee function, quality of life, satisfaction with treatment and subsequent surgical interventions on the target knee performed outside the study site, i.e. the duration of follow-up is not standardized. All clinical sites having treated more than 8 patients with NOVOCART® Basic between 2014 and 2017 will be contacted for participation. Participating clinical sites will be asked to collect informed consent from their patients to document relevant data from their medical charts and to complete the questionnaires. Consenting patients will send the signed informed consent form(s) and the completed questionnaires back to the study site. The date of questionnaire completion is regarded the end of observation for an individual patient. For data documentation, a medical documentation specialist authorized by TETEC AG will be given access to the patient files, the informed consent forms, and the completed questionnaires. The relevant data will be entered directly into an electronic database by the medical documentation specialist. Only data from patients who have given informed consent to study participation will be documented. If available, post-MAC MRIs will be collected and reviewed by independent experts.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • for the biological reconstruction of localized full-layer cartilage damage (III and IV degree defects pursuant to the ICRS classification) in the knee joint.
  • Treatable defects include:
  • Cartilage damage caused by trauma
  • Defects due to osteochondrosis dissecans
  • Smaller focally-limited, degenerative cartilage damage
  • Patients aged between 18 and 55 years
  • Cartilage defect sizes from 1.5 to 4 cm²
  • Deep osseous substance defects require prior osseous reconstruction. The indication should be confirmed using arthroscopy.

Exclusion criteria

  • Patients with known allergies to bovine collagen.
  • Infected joints or infected wounds/areas near the joint, arthritis or inflammatory joint diseases of any type are contraindicated.
  • More than two corresponding cartilage defects
  • Instability of the knee, subtotal/total meniscus resection
  • Varus/valgus malpositions (corrective surgery required in such cases)
  • Haemorrhagic diathesis of various origins
  • Applications which are not listed in the Indications section.

Treatment and study plan

MAC with NOVOCART Basic

Device

NOVOCART® Basic is a biphasic, collagen-based matrix to support the biological reconstruction of localized and full-thickness cartilage damages after treatment with bone marrow stimulation techniques (microfracture). The procedure is called matrix associated chondrogenesis (MAC). It is a single-step procedure.

NOVOCART® Basic is tailored to fit the prepared defect size and is inserted in the defect area after microfracture. The NOVOCART® Basic device component is fully resorbed over a period of a few months as new reparative cartilage tissue is generated and integrated with the surrounding host tissue.

Other names: MAC

Primary outcomes

  1. Assessment of the safety of NOVOCART® Basic

    Time frame: Up to 5 years

    Number of participants with treatment related adverse device effects or adverse events related to the procedure involved

Secondary outcomes

  1. Rate of therapy change

    Time frame: Up to 5 years

    Rate of therapy change (other surgical cartilage repair modality applied to the MAC treated defect(s))

  2. Rate of adverse device effects

    Time frame: Up to 5 years

    Number of treatment related adverse device effects

  3. Rate of device deficiencies

    Time frame: Up to 5 years

    Number of device deficiencies

  4. Rate of adverse events related to the procedure involved

    Time frame: Up to 5 years

    Number of adverse events related to the procedure involved

  5. KOOS

    Time frame: Up to 5 years

    Questionnaire: Knee injury and Osteoarthrisits Outcome Score (KOOS)(KOOS5 and subscores)

  6. IKDC

    Time frame: Up to 5 years

    Questionnaire: International Knee Documentation Committee (IKDC2000) subjective score

  7. EQ-5D-5L

    Time frame: Up to 5 years

    Quality of life (EQ-5D-5L index)

  8. Patient satisfaction with treatment

    Time frame: Up to 5 years

    5 questions to patient satisfaction with treatment

  9. MRI if available

    Time frame: Up to 5 years

    Magnetic Resonance Observation of Cartilage Repair Tissue (MOCART) score will be used for assessment of the in vivo performance, if post-MAC MRIs are available from clinical routine

Sponsors and collaborators

Lead sponsor

Tetec AG

Industry

Collaborators

  • Aesculap AG
  • Winicker Norimed GmbH

Registry information

Official study title

Non-interventional Study to Evaluate the Safety and Performance of NOVOCART® Basic and the Clinical Outcome of MAC With NOVOCART® Basic in Patients Treated for Cartilage Defects in the Knee.

Acronym: NBasic

Important dates

Study start
2018
Primary completion
2019
Study completion
2019
First posted
Jan 17, 2019
Registry last updated
Apr 2, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.